Category: In the News

We are excited to share that Professor Tore Bengtsson and  Dr. Hamza Bokhari will be attending Endocrine Metabolic GPCRs 2026 in Liverpool (9–10 Feb)!

Hamza will be presenting our latest research:

“A GRK-Biased β₂-Adrenergic Receptor Agonist Induces Coordinated Fat Loss and Muscle Gain via Pathway-Selective Signaling.”

Our work underscores how pathway-selective GPCR modulation can drive favorable metabolic outcomes while minimizing adverse effects, which has exciting implications for metabolic diseases and muscle wasting.

Looking forward to engaging discussions and new collaborations at EMGPCRs2026!

More about the conference: https://www.endocrinology.org/events/endocrine-metabolic-gpcrs/endocrine-metabolic-gpcrs-2026

The future of obesity treatment isn’t just about weight loss; it’s about the quality and durability of that loss. 17th of November, Atrogi will be at the London Life Sciences Week and the LSX Investival Showcase and will be represented by Dr. Hamza Bokhari to discuss how we are leading this new paradigm.

Atrogi is now a Phase 2-ready company with a differentiated platform of oral beta-2 agonists. While the field has made incredible strides, the challenges of muscle loss and weight regain remain. Our lead asset is designed to solve this. It is a foundational oral therapy that delivers high-quality, muscle-preserving weight loss, both as a standalone treatment and as a crucial add-on to any potent appetite suppressant.

Furthermore, our platform’s focus on muscle biology is highly translatable. We believe this creates a significant opportunity to address other diseases where muscle wasting is a core problem, including high-value rare disease indications.
We are keen to connect with investors and potential pharma partners who share our vision for defining the next generation of metabolic and muscular health. Please contact us to schedule a meeting.

Looking forward to BIO Europe in Vienna next week! Our focus will be the future of high-quality weight loss.
The success of incretins has created a critical unmet need for a solution to the muscle loss and subsequent weight regain that follows. We have developed a Phase II ready, oral therapy designed to solve this. Our approach, built on a validated GPCR platform, is to deliver a foundational muscle-preserving treatment that can be used as a standalone or as a crucial add-on to current appetite suppressants.

We are keen to connect with investors and potential partners who share our vision for defining the next generation of metabolic therapeutics. Message us to schedule a meeting!

https://longevity.technology/news/new-muscle-activating-therapy-could-support-healthier-aging/